NCT01060384 - Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 29, 2010

Primary Completion Date

October 25, 2016

Study Completion Date

January 1, 2018

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG

Lenalidomide

"Dose Cohort -1\^ 10mg daily on Days 1-21 every 28 days~Dose Cohort +1\^\^ 15mg daily on Days 1-21, every 28 days~Dose Cohort +2 20 mg daily on Days 1-21, every 28 days~Dose Cohort #3 25 mg daily on Days 1-21, every 28 days~\^Used only if Dose Cohort +1 requires further reduction~\^\^Starting Dose Cohort in Phase I"

DRUG

ofatumumab

8 weekly infusions of ofatumumab 1000mg.

Trial Locations (2)

68198

University of Nebraska Medical Center, Omaha

68803

Saint Francis Medical Center, Grand Island